Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
A randomized trial of therapies for type 2 diabetes and coronary artery disease
New England Journal of Medicine, 06/10/09
BARI 2D Study Group et al. – Findings show no significant difference overall in rates of death and major cardiovascular events between pts undergoing prompt revascularization and those undergoing medical therapy or between strategies of insulin sensitization and insulin provision.
Methods- Randomization of 2368 pts with both type 2 diabetes and heart disease to either prompt revascularization with intensive medical therapy or intensive medical therapy alone and to undergo either insulin-sensitization or insulin-provision therapy
- Primary endpoints: rate of death and composite of death, myocardial infarction, or stroke (major cardiovascular events)
- Randomization stratified by choice of percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) as the more appropriate intervention
- At 5 yrs, rates of survival did not differ significantly between revascularization (88.3%) and medical-therapy group (87.8%) or between insulin-sensitization (88.2%) and insulin-provision group (87.9%)
- Rates of freedom from major cardiovascular events did not differ significantly among groups: 77.2% in revascularization vs 75.9% in medical-treatment group and 77.7% in insulin-sensitization vs 75.4% in insulin-provision group
- In PCI stratum, no significant difference in primary endpoints between revascularization vs medical-therapy group
- In CABG stratum, significantly lower rate of major cardiovascular events in revascularization (22.4%) vs medical-therapy group (30.5%) for interaction between stratum and study group
- Adverse events and serious adverse events generally similar among the groups
- Severe hypoglycemia more frequent in insulin-provision (9.2%) vs insulin-sensitization group (5.9%)
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Acute Coronary Syndromes: Diagnosis and Management, Part I
Mayo Clinic Proceedings, 10/05/09
Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in older patients
Archives of Gerontology and Geriatrics, 10/14/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Hemoglobin A1C and diabetes diagnosis: The Rancho Bernardo Study
Diabetes Care, 10/28/09
Today in Vascular Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


